Patents by Inventor Stephen Damment

Stephen Damment has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of anagrelide for treating cancer
    Patent number: 11324746
    Abstract: The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 10, 2022
    Assignee: AROVELLA THERAPEUTICS LIMITED
    Inventors: Stephen Damment, Richard Franklin, Jorge D. Erusalimsky
  • Cyclodextrin-panobinostat adduct
    Patent number: 11235068
    Abstract: The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct. Also provided is an artificial cerebrospinal fluid (CSF) solution comprising the cyclodextrin-panobinostat adduct and medical uses of the cyclodextrin-panobinostat adduct, including in the treatment of brain tumours.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: February 1, 2022
    Assignee: MIDATECH LTD.
    Inventors: Tom Coulter, Stephen Damment, Alessandro Pace, Daniel Palmer
  • Cyclodextrin-Panobinostat Adduct
    Publication number: 20200368367
    Abstract: The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct. Also provided is an artificial cerebrospinal fluid (CSF) solution comprising the cyclodextrin-panobinostat adduct and medical uses of the cyclodextrin-panobinostat adduct, including in the treatment of brain tumours.
    Type: Application
    Filed: June 11, 2020
    Publication date: November 26, 2020
    Inventors: Tom Coulter, Stephen Damment, Alessandro Pace, Daniel Palmer
  • Cyclodextrin-panobinostat adduct
    Patent number: 10722597
    Abstract: The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct. Also provided is an artificial cerebrospinal fluid (CSF) solution comprising the cyclodextrin-panobinostat adduct and medical uses of the cyclodextrin-panobinostat adduct, including in the treatment of brain tumours.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: July 28, 2020
    Assignee: MIDATECH LTD.
    Inventors: Tom Coulter, Stephen Damment, Alessandro Pace, Daniel Palmer
  • CYCLODEXTRIN-PANOBINOSTAT ADDUCT
    Publication number: 20190151468
    Abstract: The present invention provides a method for producing a cyclodextrin-panobinostat adduct, comprising: a) providing a first aqueous solution comprising a buffering agent, the solution having a pH in the range 2.0 to 4.0; b) dissolving panobinostat in said first aqueous solution to provide a second aqueous solution; and c) mixing said second aqueous solution comprising panobinostat with a third aqueous solution comprising a cyclodextrin to form a fourth aqueous solution comprising a cyclodextrin-panobinostat adduct. Also provided is an artificial cerebrospinal fluid (CSF) solution comprising the cyclodextrin-panobinostat adduct and medical uses of the cyclodextrin-panobinostat adduct, including in the treatment of brain tumours.
    Type: Application
    Filed: March 29, 2017
    Publication date: May 23, 2019
    Inventors: Tom Coulter, Stephen Damment, Alessandro Pace, Daniel Palmer
  • USE OF ANAGRELIDE FOR TREATING CANCER
    Publication number: 20170360793
    Abstract: The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 21, 2017
    Inventors: Stephen DAMMENT, Richard FRANKLIN, Jorge D. ERUSALIMSKY
  • Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
    Publication number: 20070104799
    Abstract: A subject with symptoms of chronic kidney disease (CKD), who does not have end-stage renal disease (ESRD), can be treated by orally administering a pharmaceutical composition as an active ingredient a therapeutically effective amount of a non-toxic lanthanum compound. Administration of a lanthanum compound can prevent the progression of CKD, treat soft tissue calcification, and treat secondary hyperparathyroidism.
    Type: Application
    Filed: November 9, 2005
    Publication date: May 10, 2007
    Applicant: SHIRE INTERNATIONAL LICENSING B.V.
    Inventors: Raymond Pratt, Isobel Webster, Stephen Damment